Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 16 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
VICT3RDeveloping and implementing VIrtual Control groups To reducE animal use in toxicology Research
HORIZON-JU-IHI-2023-05-01 · 2024 · Official record ↗
SAIFASerbian Artificial Intelligence Factory Antenna
HORIZON-JU-EUROHPC-2025-AIFA-01 · 2026 · Official record ↗
AFRICAI-RIA Pan-African Research Infrastructure for Collaborative Biomedical Imaging and Artificial Intelligence in Respiratory Care
HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage · 2025 · Official record ↗
BRAIN PPBulgarian Robotics & AI Nexus - Where Human Ingenuity meets Artificial Intelligence
HORIZON-JU-EUROHPC-2025-AI-01-IBA-01 · 2025 · Official record ↗
SkincAIrEarly detection and management of SKIN-related negleCted tropical diseases using Artificial Intelligence in sub-saharan afRica (SkincAIr)
HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage · 2025 · Official record ↗
IT4LIAItaly for Artificial Intelligence
HORIZON-JU-EUROHPC-2025-AI-01-IBA-01 · 2025 · Official record ↗
BeGREENBeyond 5G Artificial Intelligence Assisted Energy Efficient Open Radio Access Network
HORIZON-JU-SNS-2022-STREAM-A-01-01 · 2023 · Official record ↗
NANCYAn Artificial Intelligent Aided Unified Network for Secure Beyond 5G Long Term Evolution
HORIZON-JU-SNS-2022-STREAM-A-01-06 · 2023 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
The action under this topic is expected to achieve the following impacts:
The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and the implementation of the 3Rs principles to replace, reduce and refine the use of animals. The action is expected also to consider and contribute to EU programmes, initiatives and policies on New Approach Methodologies (NAMs) such as the future European Research Area (ERA) action on accelerating NAMs to advance biomedical research and testing of medicinal products and medical devices.
[1] Transforming animal study toxicology reports into structured, harmonized data using large language models
[2] European Directive on the protection of animals used for scientific purposes
The action under this topic must contribute to all of the following outcomes:
* An AI Foundation Toxicology Model is a large-scale, pre-trained machine learning system that learns generalisable representations of toxicological biology and chemistry from diverse, multimodal datasets, enabling broad applicability across safety assessment tasks with minimal task-specific training.
[1] ICH M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. In: International Conference on Harmonisation (ICH). Topic M3(R2); 2009.
Regulatory guidelines e.g. ICH M3(R2) for nonclinical safety assessment of new small molecule medicines have historically required toxicity studies in two species, typically one rodent and one non-rodent, to maximise the likelihood of detecting adverse effects, improve the translatability to humans and guide patient dosing and monitoring. This two species approach is increasingly challenged by ethical considerations, long and costly study durations, limited reproducibility, and uncertainty regarding human relevance [1], [2]. In parallel, scientific progress in mechanistic toxicology, advanced in vitro systems (e.g. organoids and micro-physiological systems), multi-omics technologies, and AI based modelling is enabling NAMs to help reduce reliance on animal models without compromising patient safety. Within the context of this topic, the AI Foundation Toxicology Model will be considered a NAM, facilitating NAM-enabled second species waivers.
In addition, the policy landscape across global jurisdictions is evolving rapidly. The European Commission is preparing a roadmap towards phasing out animal testing for chemical assessment safety, expected in 2026 [3]; the European Medicines Agency (EMA) has increased its focus on emerging NAMs through horizon-scanning and dedicated working groups [4]; the UK Government has published the Replacing Animals in Science strategy [5] and the United States Food and Drug Administration (FDA) has published a dedicated roadmap for reducing animal testing in preclinical safety studies [6]. Collectively, these initiatives highlight the need for robust evidence, data integration, validated methods and coordinated stakeholder action to support credible alternatives to animal testing.
A weight-of-evidence approach can eliminate unnecessary animal tests by integrating and assessing diverse data sets as well as determining whether the available evidence is sufficient or additional nonclinical testing is required to address potential safety concerns. The value of this evidence depends on its quality, consistency, human relevance, and the nature and severity of observed effects. Currently, the absence of standardised, data-driven methods means decisions can vary across reviewers and jurisdictions, creating an uncertainty which discourages changes from being made to the current process. A more structured, reproducible, validated, and evidence-based approach would support consistent, transparent, and well-justified decision-making on whether second species studies could be waived.
This topic aims to address and standardise the waiver process for second species chronic and sub-chronic small molecule general toxicology studies by developing a transparent, AI-driven Foundation Toxicology Model. The model should be underpinned by diverse, standardised, high quality in vivo datasets, encompassing all modalities of medicines, and supported by a robust weight-of-evidence framework. The most appropriate single species should be selected early in the drug development programme based on target affinity and functions, metabolite profiling, etc. The main context of use of the AI Foundation Toxicology Model is to predict whether testing in a second species will provide additional safety-relevant information. If toxicity predictions are equal across rodent and non-rodent species, priority should be given to the reduction of non-rodent chronic toxicity testing.
Although the context of use for this topic should be focused on waiving second species testing for chronic and sub-chronic small molecule studies, the project’s actions, sustainability plan plus the ongoing development and evolution of the model should provide the opportunity to assess appropriate single species selection and encompass the broadening of the context of use to enable the waiving of single species chronic testing in small molecules and other modalities, such as oligonucleotides. Therefore, relevant data sources and their provision should enable this broader and longer-term goal. Selection of the appropriate single animal species for preclinical safety evaluations for biotechnology-derived pharmaceuticals in line with ICH S6 [7] should be considered within the scope of this project if the relevant data provision is sufficient to enable this functionality.
This topic should build upon, among others, the outcomes, learnings, data sharing structures, and methodologies of previous IMI/IHI projects that improve the predictability, feasibility and reliability of pre clinical safety assessments — such as BigPicture, eTRANSAFE , eTOX , imSAVAR , and VICT3R — as well as other relevant European, international and national initiatives such as Animal free safety assessment of chemicals: Project cluster for implementation of novel strategies (ASPIS) and NC3Rs-led efforts like the Virtual Second Species [8] initiative and the Two Species project [9]. Preliminary analysis from the NC3Rs Two Species project predicts that it would be possible to avoid conducting studies in non-rodents (e.g. dog or non-human primate) in >60% of the small molecule drugs that enter Phase II globally each year [10].
By fostering collaboration among pharmaceutical companies, regulatory agencies, academic institutions, SMEs, and patient advocacy groups, the action generated by this topic should seek to enhance patient safety, reduce reliance on animal testing, streamline medicine development timelines, lower associated costs, and boost the global competitiveness of the pharmaceutical industry within the European Union.
To fulfil this aim, the proposal should:
1. Consolidate and evaluate data sources
2. Select and optimise AI methods
Applicants should ensure that, in order to support regulatory acceptance and the scientific robustness of the AI Foundation Toxicology Model, it is built using a structured and transparent AI methodology encompassing:
In parallel, other approaches should be assessed in case a foundation model does not provide the solution. This could encompass decision-tree approaches, Bayesian statistical methods and/or more classical Machine Learning (ML) approaches.
3. Develop and validate the AI Foundation Toxicology Model
4. Establish a standardised weight-of-evidence framework
5. Prepare for regulatory uptake and long-term sustainability
[1] Prior et al. (2020). Opportunities for use of one species for longer-term toxicology testing during drug development: a cross industry evaluation. Regulatory Toxicology and Pharmacology. 29;113:104624
[2] Prior et al., (2024). Exploring Greater Flexibility for Chronic Toxicity Study Designs to Support Human Safety Assessment While Balancing 3Rs Considerations International Journal of Toxicology. 43(5):456-463.
[3] European Commission – Roadmap towards phasing out animal testing
[4] EMA – New Approach Methodologies Horizon Scanning Report
[5] UK Government – Replacing Animals in Science Strategy
[6] FDA – Roadmap to Reducing Animal Testing in Preclinical Safety Studies
[7] Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
[8] NC3Rs Virtual Second Species - Applying advanced computational and mathematical modelling approaches to develop a suite of virtual dog tissues and organs to model toxicological endpoints for new chemical entities
[9] Review of the use of two species in regulatory toxicology studies | NC3Rs
[10] Passini et al (2025). OS02-10 Analysis of the use of two species in regulatory toxicology studies for molecules following ICH M3(R2) Toxicology Letters (EUROTOX 2025)
[11] SEND specifies a way to collect and present non-clinical data in a consistent format, a requirement for data submission to regulators
[12] Innovative Science and Technology Approaches for New Drugs (ISTAND) Program, FDA
[13] Assessment List for Trustworthy Artificial Intelligence (ALTAI)
1. Admissibility conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System :
2. Eligible countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
described in Annex B of the Work Programme General Annexes and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the IHI JU Work Programme (WP)
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
described in Annex D of the Work Programme General Annexes and in the ''Conditions of the Calls for proposals and Calls management rules'' section of the IHI JU Work Programme (WP)
5b. Evaluation and award: Submission and evaluation processes
described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
described in Annex G of the Work Programme General Annexes.
described in the ''Conditions of the Calls for proposals and Calls management rules'' section of the the IHI JU Work Programme (WP)
Where relevant, templates of the reference documents and associated guidance can be found on the IHI JU website.
Regarding the application forms for submitting proposals, the relevant templates and annexes are available to download in the submission system of the Funding and Tender Opportunities portal.
The IHI JU 13th Call for proposals full topics text is available here.
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Evaluation form (RIA Actions – single and two-stage Calls procedure)
IHI JU Evaluation form for Research and Innovation Actions
Proposal Templates Part A and Part B (RIA Actions – single and second stage of two-stage procedure)
1. For 1st stage of two-stage calls
Compulsory annex for Short proposals. The “type of participants” is an IHI specific annex related to Short proposals (first stage of two-stage calls). It can be found here. Instructions on how to fill in this template can be found here.
2. For 2nd stage of two-stage calls
a) Annex to the Budget and Type of participants
Compulsory annex for Full proposals, which complements the budget figures already included in the proposal budget in PART A. Its purpose is to correctly guide the consortium in providing IHI-specific budget items (e.g. IKOP, IKAA, FC PAID, FC RECEIVED) and to comply with IHI additional eligibility criteria (e.g. 45% industry contribution).
The excel document template can be found here.
Instructions on how to fill in the budget can be found here.
Instructions on how to fill the type of participants can be found here.
b) Annex: Declaration of in-kind contribution commitment
Compulsory annex for the second stage of two-stage calls and single-stage calls.
The word document template can be found here.
c) Annex: In-kind contributions to additional activities (IKAA)
Compulsory annex for the second stage of two-stage calls and single-stage calls and when the proposal includes IKAA.
The ‘’In-kind contributions to additional activities (IKAA)’’ is an IHI specific annex.
The excel template can be found here.
d) Annex: Essential information for clinical studies
Compulsory annex for the second stage of two-stage calls and single-stage calls which must be uploaded as a separate document in the submission system. If your proposal does not include clinical studies, please upload a statement declaring that your proposal does not include clinical studies.
The information on clinical studies annex can be found here.
d) Annex: Ethics
Optional annex for the second stage of two-stage calls and single-stage calls. Part A of the proposal includes an ethics self-assessment. However, if the proposal raises many serious ethical issues, the character count in Part A may not be enough for applicants to provide all the information needed. If this is the case for you, you should provide any additional information on the ethical aspects of your proposal in a separate document and upload it as an ethics annex. Note that there is no specific template for this annex.
3. Model Grant Agreements (MGA)
HE MGA
Additional documents:
Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014 (in short Single Basic Act ‘SBA’ or Council Regulation (EU) 2021/2085).
IHI JU Work Programme (WP)
Strategic Research and Innovation Agenda (SRIA)
IHI JU Guide for Applicants
IHI JU FAQs
Horizon Europe Reference Documents :
HE Main Work Programme 2026-2027 – General Annexes
HE Programme Guide
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-16
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.